Hala Abou El Naja

Hala Abou El Naja

Auto-generated profile, based on publicly available information

Hala Abou El Naja

Ministry of Public Health, Epidemiological Surveillance Program

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Microbial Genomics
Verified
Journal Article
Open access
GMGeorgi Merhi
Georgi Merhi
ATAlexander J. Trotter
Alexander J. Trotter
LMLeonardo de Oliveira Martins
Leonardo de Oliveira Martins
JKJad Koweyes
Jad Koweyes
TLThanh Le-Viet
Thanh Le-Viet
STSima Tokajian
Sima Tokajian
The COVID-19 pandemic continues to expand globally, with case numbers rising in many areas of the world, including the Eastern Mediterranean Region. Lebanon experienced its largest wave of COVID-19 infections from January to April 2021. Limited genomic surveillance was undertaken, with just 26 SARS-CoV-2 genomes available for this period, nine of which were from travellers from Lebanon detected by other countries. Additional genome sequencing is thus needed to allow surveillance of variants in circulation. In total, 905 SARS-CoV-2 genomes were sequenced using the ARTIC protocol. The genomes were derived from SARS-CoV-2-positive samples, selected retrospectively from the sentinel COVID-19 surveillance network, to capture diversity of location, sampling time, sex, nationality and age. Although 16 PANGO lineages were circulating in Lebanon in January 2021, by February there were just four, with the Alpha variant accounting for 97 % of samples. In the following 2 months, all samples contained the Alpha variant. However, this had changed dramatically by June and July 2021, when all samples belonged to the Delta variant. This study documents a ten-fold increase in the number of SARS-CoV-2 genomes available from Lebanon. The Alpha variant, first detected in the UK, rapidly swept through Lebanon, causing the country's largest wave to date, which peaked in January 2021. The Alpha variant was introduced to Lebanon multiple times despite travel restrictions, but the source of these introductions remains uncertain. The Delta variant was detected in Gambia in travellers from Lebanon in mid-May, suggesting community transmission in Lebanon several weeks before this variant was detected in the country. Prospective sequencing in June/July 2021 showed that the Delta variant had completely replaced the Alpha variant in under 6 weeks.

24 June 2022 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
STStefano Tempia
Stefano Tempia
HNHala Abou El Naja
Hala Abou El Naja
ABAmal Barakat
Amal Barakat
AAAbdinasir Abubakar
Abdinasir Abubakar
WKWasiq Khan
Wasiq Khan

23 June 2022 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
AAAbdinasir Abubakar
Abdinasir Abubakar
WKWasiq Khan
Wasiq Khan
HNHala Abou El Naja
Hala Abou El Naja
LALubna Al Ariqi
Lubna Al Ariqi
VBVictoria D Bélorgeot
Victoria D Bélorgeot
SHStephanie J Hauck
Stephanie J Hauck

11 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
GMGeorgi Merhi
Georgi Merhi
ATAlexander J. Trotter
Alexander J. Trotter
LMLeonardo de Oliveira Martins
Leonardo de Oliveira Martins
JKJad Koweyes
Jad Koweyes
TLThanh Le-Viet
Thanh Le-Viet
STSima Tokajian
Sima Tokajian
Background The COVID-19 pandemic continues to expand globally, with case numbers rising in many areas of the world, including the Eastern Mediterranean Region. Lebanon experienced its largest wave of COVID-19 infections from January to April 2021. Limited genomic surveillance was undertaken, with just twenty six SARS-CoV-2 genomes available for this period, nine of which were from travellers from Lebanon detected by other countries. Additional genome sequencing is thus needed to allow surveillance of variants in circulation. Methods Nine hundred and five SARS-CoV-2 genomes were sequenced using the ARTIC protocol. The genomes were derived from SARS-CoV-2-positive samples, selected retrospectively from the sentinel COVID-19 surveillance network, to capture diversity of location, sampling time, gender, nationality and age. Results Although sixteen PANGO lineages were circulating in Lebanon in January 2021, by February there were just four, with the Alpha variant accounting for 97% of samples. In the following two months, all samples contained the Alpha variant. However, this had changed dramatically by June and July, when all samples belonged to the Delta variant. Discussion This study provides a ten-fold increase in the number of SARS-CoV-2 genomes available from Lebanon. The Alpha variant, first detected in the UK, rapidly swept through Lebanon, causing the country’s largest wave to date, which peaked in January 2021. The Alpha variant was introduced to Lebanon multiple times despite travel restrictions, but the source of these introductions remains uncertain. The Delta variant was detected in Gambia in travellers from Lebanon in mid-May, suggesting community transmission in Lebanon several weeks before this variant was detected in the country. Prospective sequencing in June/July 2021 showed that the Delta variant had completely replaced the Alpha variant in under six weeks.

28 June 2022 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
HNHala Abou El Naja
Hala Abou El Naja
STStefano Tempia
Stefano Tempia
ABAmal Barakat
Amal Barakat
AEAmgad Elkholy
Amgad Elkholy
AAAmir Aman
Amir Aman
AAAbdinasir Abubakar
Abdinasir Abubakar
Introduction A global reduction in influenza virus activity during the COVID-19 pandemic has been observed, including in the Eastern Mediterranean Region (EMR). However, these changes have not been thoroughly evaluated scientifically in the EMR. Objective We aim to present data on seasonal influenza activity during the pre-pandemic period (2016–2019) and compare it to the pandemic period (2020–2021) in EM countries. Methods Epidemiological and virological influenza surveillance data were retrieved from both WHO FluNet and EMFLU networks. Four pre-pandemic analytical periods were used in the comparative analysis. We compiled and calculated weekly aggregated epidemiological data on the number of enrolled patients, number of tested specimens and number of positive influenza specimens. Results 19 out of the 22 countries of the EMR have functioning sentinel influenza surveillance systems, and these countries report the influenza data to WHO through FluNet and EMFLU. The number of enrolled patients and tested specimens increased gradually from 51 384 and 50 672, respectively, in 2016–2017 analytical period to 194 049 enrolled patients and 124 697 tested specimens in 2019–2020. A decrease has been witnessed in both enrolled patients and tested specimens in 2020–2021 ‘pandemic period’ (166 576 and 44 764, respectively). By comparing influenza activity of analytical period 2020–2021 with that of 2016–2019 analytical periods, we found that there has been a decrease in influenza positivity rate in the EMR by 89%. Conclusion The implementation of non-pharmaceutical interventions to control the COVID-19 pandemic may have also impacted the spread of influenza viruses. The low circulation of influenza viruses during 2020–2021 and the associated potential immunity gap may result in increased transmission and severity of post-pandemic influenza seasons. This necessitates high vigilance to continuous data and virus sharing to monitor circulating viruses in a timely fashion to reduce the intensity and severity of future influenza epidemics.

24 January 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ZFZeina Farah
Zeina Farah
NHNadine Haddad
Nadine Haddad
HNHala Abou El Naja
Hala Abou El Naja
MSMajd Saleh
Majd Saleh
PMPamela Mrad
Pamela Mrad
NGNada Ghosn
Nada Ghosn
Introduction In Lebanon, the nationwide vaccination against COVID-19 was launched in February-2021 using Pfizer-BioNTech vaccine and prioritizing elderly, persons with comorbidities and healthcare workers. Our study aims to estimate the post-introduction vaccine effectiveness (VE) of Pfizer-BioNTech in preventing COVID-19 hospitalization among ≥75 years in Lebanon. Methods A case-control study design was used. Cases were Lebanese, ≥75 years and hospitalized with positive PCR result during April-May 2021. Cases were randomly selected from the COVID-19 database of the Epidemiological Surveillance Unit(ESU) at the Ministry of Public Health(MOPH). Each case was matched by age and locality to 2 controls. Controls were hospitalized, non-COVID-19 patients with negative PCR result, randomly selected from the MOPH hospital admission database. VE was calculated for fully and partially vaccinated, using multivariate conditional logistic regression analyses. Results 345 cases and 814 controls were recruited. Half were females, with a mean age of 83 years. 14 cases(5%) and 143 controls(22%) were fully vaccinated. Bivariate analysis showed significant association with: gender, month of confirmation/admission, general health, chronic medical conditions, main income source and living arrangement. After adjusting for month of admission and gender, multivariate analysis yielded a VE of 82% (95%CI = 69%-90%) against COVID-19 associated hospitalization for those fully vaccinated and 53% (95%CI = 23%-71%) for those partially vaccinated (≥14 days of first or within 14 days of second dose). Conclusions Our study showed that Pfizer-BioNTech vaccine is effective in reducing risk for COVID-19– associated hospitalization in Lebanese elderly(≥75 years). Additional studies are warranted to explore vaccine effectiveness in reducing hospitalization in younger age groups, as well as in reducing covid-19 infections.